GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HLB Pharmaceutical Co Ltd (XKRX:047920) » Definitions » EV-to-Revenue

HLB Pharmaceutical Co (XKRX:047920) EV-to-Revenue : 4.35 (As of Jun. 03, 2025)


View and export this data going back to 2015. Start your Free Trial

What is HLB Pharmaceutical Co EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, HLB Pharmaceutical Co's enterprise value is ₩601,268 Mil. HLB Pharmaceutical Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was ₩138,277 Mil. Therefore, HLB Pharmaceutical Co's EV-to-Revenue for today is 4.35.

The historical rank and industry rank for HLB Pharmaceutical Co's EV-to-Revenue or its related term are showing as below:

XKRX:047920' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.12   Med: 4.4   Max: 13.13
Current: 4.35

During the past 11 years, the highest EV-to-Revenue of HLB Pharmaceutical Co was 13.13. The lowest was 1.12. And the median was 4.40.

XKRX:047920's EV-to-Revenue is ranked worse than
71.02% of 973 companies
in the Drug Manufacturers industry
Industry Median: 2.43 vs XKRX:047920: 4.35

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-06-03), HLB Pharmaceutical Co's stock price is ₩19040.00. HLB Pharmaceutical Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 was ₩4,025.13. Therefore, HLB Pharmaceutical Co's PS Ratio for today is 4.73.


HLB Pharmaceutical Co EV-to-Revenue Historical Data

The historical data trend for HLB Pharmaceutical Co's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HLB Pharmaceutical Co EV-to-Revenue Chart

HLB Pharmaceutical Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.89 5.72 2.77 3.33 5.55

HLB Pharmaceutical Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.37 3.94 5.84 5.55 4.59

Competitive Comparison of HLB Pharmaceutical Co's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, HLB Pharmaceutical Co's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HLB Pharmaceutical Co's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, HLB Pharmaceutical Co's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where HLB Pharmaceutical Co's EV-to-Revenue falls into.


;
;

HLB Pharmaceutical Co EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

HLB Pharmaceutical Co's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=601267.595/138276.94
=4.35

HLB Pharmaceutical Co's current Enterprise Value is ₩601,268 Mil.
HLB Pharmaceutical Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩138,277 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HLB Pharmaceutical Co  (XKRX:047920) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

HLB Pharmaceutical Co's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=19040.00/4025.132
=4.73

HLB Pharmaceutical Co's share price for today is ₩19040.00.
HLB Pharmaceutical Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩4,025.13.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HLB Pharmaceutical Co EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of HLB Pharmaceutical Co's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


HLB Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
67, Euiui-ro, Songpa-gu, MK Tower 9th Floor, Seoul, KOR
HLB Pharmaceutical Co Ltd is a research-oriented pharmaceutical company. It is engaged in developing medicines and drugs. Its products include skeletal muscle relaxant, pain relief drugs, blood pressure-lowering agents, local anaesthetics, digestive system drugs, antacids, vitamins, haemorrhoid solvents, insect repellents, peptic ulcer solvents, and other products.

HLB Pharmaceutical Co Headlines

No Headlines